METAVIVOR PROGRESS REPORT

PI Name: Antonio Giordano MD PHD

Grant title: Phase 1 clinical trial of polo-like kinase 1 inhibition with paclitaxel in metastatic triple negative breast cancer

Date: February 13, 2023

**Lay Description of Important Outcomes**

The natural history of TNBC is to become resistant to chemotherapy and patients with this type of breast cancer have a poor survival. At the moment, novel approaches for the treatment of metastatic TNBC are needed to improve clinical outcomes.

In this proposal we are testing for the first time in humans the safety and preliminary efficacy of onvansertib in combination with paclitaxel in patients with metastatic TNBC. Onvansertib is a PLK1 inhibitor that can be administered by mouth. The primary goal of this study is to define the safety and tolerability of different doses of onvansertib used in combination with intravenous paclitaxel and to determine the optimal dose of the combination in patients with metastatic TNBC.

The clinical trial is ongoing and open to enrollment at Dana-Farber and Massachusetts General Hospital in Boston. We expect to complete the phase Ib portion of this proposal and identify RP2D in first quarter 2024.